<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<pubmed-document>
<record>
<header>
<identifier>15248398</identifier>
<setSpec>0210-4806</setSpec>
</header>
<metadata xmlns="http://example.org/myapp/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://example.org/myapp/schema.xsd">
<dc:author>Ropero, R M</dc:author>
<dc:author>Martín, R M</dc:author>
<dc:author>Rodríguez, F J</dc:author>
<dc:author>Angulo, J C</dc:author>
<dc:author>Colas, B</dc:author>
<dc:author>López, J I</dc:author>
<dc:author>Zapata, P D</dc:author>
<dc:author>López-Ruiz, P</dc:author>
<dc:author>González, F J</dc:author>
<dc:description xml:lang="en">We review the mechanisms involved in prostatic growth based on androgens and product of neuroendocrine secretion, with special reference to the role of somatostatin (SS) in the inhibition of neoplastic growth. Our contributions in the field confirm the antiproliferative effect of SS on the prostate is mediated by phosphotyrosine phosphatase SHP-1, that is present in human prostate. This enzyme plays a role in the control of prostatic cell proliferation and in the progression of prostate cancer. Besides, we consider its presence may determine the therapeutic potential of SS in the control of prostate cancer.</dc:description>
<dc:type>English Abstract</dc:type>
<dc:language>es</dc:language>
<dc:date>2004 Apr </dc:date>
<dc:title xml:lang="es">Fosfotirosina fosfatasa SHP-1, somatostatina y cáncer de próstata.</dc:title>
<dc:title xml:lang="en">[Phosphotyrosine phosphatase SHP-1, somatostatin and prostate cancer].</dc:title>
<dc:publisher>Actas urologicas espanolas</dc:publisher>
</metadata>
</record>
</pubmed-document>
